Insider Trading April 13, 2026 10:03 PM

ASP Isotopes COO Sells $112.8K in Stock as Company Reports Strong Q4 Revenue Growth

Robert Ainscow executed a Rule 10b5-1 sale of 25,000 shares; ASP Isotopes posts a 480% year-over-year revenue jump in Q4 2025

By Hana Yamamoto ASPI
ASP Isotopes COO Sells $112.8K in Stock as Company Reports Strong Q4 Revenue Growth
ASPI

Robert Ainscow, Chief Operating Officer of ASP Isotopes Inc., sold 25,000 shares on March 6, 2026, under a pre-established Rule 10b5-1 plan for $112,775. The transaction comes amid a six-month 64% decline in the stock, even as the company reported a 480% increase in Q4 2025 revenue and analysts set price targets between $11 and $13.

Key Points

  • COO Robert Ainscow sold 25,000 shares under a Rule 10b5-1 plan on March 6, 2026, generating $112,775 in proceeds.
  • ASP Isotopes’ stock has fallen 64% over the past six months but is currently trading at $5.06; third-party analysis places price targets between $11 and $13.
  • The company reported a 480% year-over-year increase in Q4 2025 revenue as it shifts from infrastructure development to commercial operations.

Robert Ainscow, Chief Operating Officer of ASP Isotopes Inc (NASDAQ: ASPI), disposed of 25,000 shares of the company’s common stock on March 6, 2026, according to a Form 4 filed with the Securities and Exchange Commission.

The transaction was carried out at a weighted average price of $4.511 per share, producing total proceeds of $112,775. Trade execution prices for the block ranged from $4.42 to $4.58. The sale was completed under a Rule 10b5-1 trading plan that Ainscow adopted on December 13, 2024.

Following the March 6 sale, Ainscow directly holds 1,512,817 shares of ASP Isotopes. The sale occurs against a backdrop of significant share-price volatility - the stock has slid 64% over the past six months, while recent quotes show the shares trading at $5.06.

Independent analysis cited in company-related research suggests the stock may be trading below intrinsic analyst assumptions. InvestingPro analysis indicates ASPI appears undervalued at current levels, with analysts’ price targets clustered in the $11 to $13 range. For investors seeking deeper coverage, Pro Research Reports covering ASPI and more than 1,400 additional U.S. equities are available through that research service.

Separately, ASP Isotopes reported a marked improvement in its operating results for the fourth quarter of 2025. The company posted total revenue that was 480% higher than the prior year period, reflecting a strategic shift from infrastructure development toward commercial operations. Management did not provide updates on mergers or acquisitions during the earnings call, and no analyst upgrades or downgrades were disclosed alongside the results.

The combination of an insider sale executed under a pre-established trading plan, a recent steep share-price decline, and robust quarter-over-quarter revenue growth presents a mixed signal for market participants. The transaction and the quarter’s financial results together offer investors specific, documented developments to weigh as they assess the company’s ongoing commercial transition.


Data points cited

  • Insider: Robert Ainscow, Chief Operating Officer
  • Shares sold: 25,000 on March 6, 2026
  • Weighted average sale price: $4.511; total proceeds: $112,775
  • Sale price range: $4.42 - $4.58
  • Post-sale direct holdings: 1,512,817 shares
  • Six-month share decline: 64%; recent trade: $5.06
  • InvestingPro analyst price targets: $11 - $13
  • Q4 2025 revenue change: +480% year-over-year

Risks

  • The insider sale was executed under a pre-established Rule 10b5-1 plan, which limits conclusions investors can draw about management’s near-term view of the business; this affects investor interpretation in small-cap equity markets.
  • Significant recent share-price decline - a 64% drop over six months - introduces market and valuation risk for shareholders and potential new investors.
  • Earnings commentary omitted updates on mergers and acquisitions and showed no analyst rating changes, leaving uncertainty around management’s strategic capital deployment and external validation by analysts.

More from Insider Trading

AEHR Test Systems director sells $745K in stock amid sharp share rally Apr 13, 2026 Pitney Bowes EVP Executes $7,969 Stock Sale as Company Reports Mixed Q4 Results and Plans Additional Debt Apr 13, 2026 Jabil Operations Chief Sells $1.2M in Stock as Company Posts Strong Q2 Apr 13, 2026 Photronics Executive Sells $525K in Stock as Company Posts Quarterly Beat and Expands Mask Capacity Apr 13, 2026 Mineralys Chief Medical Officer Disposes of 2,170 Shares, Exercises Equivalent Options Apr 13, 2026